Flash Finance

Hester Biosciences LimitedHESTERBIOCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹2,236.50
MCap ₹1,903 Cr · P/E 13.9
Hester Biosciences Limited — Stock analysis & AI research Hester Biosciences Limited — Multibagger AI analysis Hester Biosciences Limited — Seasonality — best & worst months Hester Biosciences Limited — Technical indicators & charts Hester Biosciences Limited — Technical setup — score, trend, support & resistance Hester Biosciences Limited — Live exchange announcements
📋 High ROE Stocks📋 High Operating Margin Stocks📋 Stocks Cheaper Than Their Industry📋 GARP Stocks (PEG Below 1) 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹77 Cr
Sales · Jun 2026
-8.4% YoY
₹23 Cr
Operating Profit · Jun 2026
+0.8% YoY
29.9%
OPM % · Jun 2026
+10.3% YoY
₹97 Cr
Net Profit · Jun 2026
+460.8% YoY
₹114.00
EPS · Jun 2026
+460.7% YoY

📝 Hester Biosciences Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Hester Biosciences Limited reported revenue of ₹77 crore for the quarter ended June 2026 (Q1 FY27), down 8.4% from ₹84 crore in the same quarter last year, and down 23.1% sequentially over the March 2026 quarter.

Net profit rose 460.8% year-on-year to ₹97 crore, from ₹17 crore. Earnings per share (EPS) came in at ₹114.00.

Operating profit stood at ₹23 crore — an operating margin (OPM) of 29.9%, compared with 27.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Hester Biosciences Limited posted revenue of ₹326 crore, a growth of 4.7% over FY25, with a net profit of ₹57 crore (up 101.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹318 crore with a net profit of ₹137 crore.

Valuation snapshot

At the current price of ₹2,236.50, HESTERBIO has a market capitalisation of ₹1,903 crore and a trailing P/E of about 13.9.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 9th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 44.28%, foreign institutional investors (FIIs) 0.31%, domestic institutional investors (DIIs) 0.08%, public shareholders 55.33% of Hester Biosciences Limited.

Promoter holding slipped from 53.73% to 44.28% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,903 Cr
Current Price ?
₹2,236.5
P/E ?
13.90below ind
Industry P/E ?
21.30
P/B ?
5.27
P/S ?
5.97
P/FCF ?
40.48
Enterprise Value ?
₹2,098 Cr
EV/EBITDA ?
21.35
PEG ?
0.53
Earnings Yield ?
3.7%
Dividend Yield ?
0.31%
Profitability & Returns
Sales (TTM) ?
₹318 Cr
OPM ?
30.8%
Profit after tax (TTM) ?
₹137 Cr
EPS (TTM) ?
₹160.90
ROCE ?
15.0%
ROE ?
37.9%
ROA ?
20.2%
Growth
Sales — latest qtr ?
₹77 Cr
PAT — latest qtr ?
₹97 Cr
YoY qtr sales growth ?
-8.4%
YoY qtr profit growth ?
460.8%
Sales growth (3y) ?
8%
Sales growth (5y) ?
9%
Profit growth (3y) ?
26%
Profit growth (5y) ?
8%
Financial Health
Debt ?
₹195 Cr
Debt to Equity ?
0.54
Interest Coverage ?
8.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
44.28%
Change in promoter holding ?
-9.45%
Pledged percentage ?
N/A
Market
Return 3 months ?
-8.6%
Return 6 months ?
50.0%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 67887067798284638284717010077 -8.4% -23.1%
Operating Profit 10141371618195192324163623 +0.8% -36.3%
Other Income 01615139-62122289 +3742.8% +4350.0%
Interest 1382756-4622153 +65.7% -40.0%
Depreciation 55444444444467 +67.4% +16.7%
Profit Before Tax 897610111213420171525102 +405.3% +308.0%
Net Profit 6744678112171491797 +460.8% +486.2%
EPS 5.337.894.814.687.528.809.8613.711.8220.3316.8510.3119.45114.00 +460.7% +486.1%
OPM % 14.1% 16.3% 18.5% 11.0% 20.1% 21.5% 22.9% 7.9% 23.4% 27.1% 33.2% 22.1% 36.1% 29.9% +10.3% -17.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹311 Cr ₹326 Cr ₹318 Cr +4.7%
Operating Profit ₹61 Cr ₹98 Cr ₹98 Cr +60.8%
OPM % 19.62% 30.12% 30.85% +53.5%
NPM % 9.14% 17.56% 42.98% +92.1%
Other Income ₹7 Cr ₹18 Cr ₹105 Cr +148.2%
Depreciation ₹17 Cr ₹18 Cr ₹21 Cr +10.1%
Interest ₹13 Cr ₹10 Cr ₹11 Cr -22.4%
EBIT ₹44 Cr ₹80 Cr ₹77 Cr +79.6%
PBT ₹39 Cr ₹77 Cr ₹159 Cr +96.0%
Tax ₹9 Cr ₹3 Cr — -67.1%
Net Profit ₹28 Cr ₹57 Cr ₹137 Cr +101.2%
EPS ₹34.19 ₹66.94 ₹160.61 +95.8%
Material Cost ₹60 Cr ₹18 Cr — -69.9%
Employee Cost ₹46 Cr ₹15 Cr — -66.8%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 9999 +0.0%
Reserves 271283306352 +15.0%
Borrowings 274244213195 -8.5%
Other Liabilities 116126126123 -2.4%
Total Liabilities 670662653678 +3.8%
Fixed Assets 259240233421 +80.7%
CWIP 1491711830 -100.0%
Investments 25303443 +26.5%
Other Assets 237221203215 +5.9%
Total Assets 670662653678 +3.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 24486564 -1.5%
Cash from Investing Activity -77-22-20-3 +85.0%
Cash from Financing Activity 42-26-52-49 +5.8%
Net Cash Flow -12-0-712 +271.4%
Free Cash Flow -54244447 +6.8%
CFO/OP 63%112%123%90% -26.8%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 1099486105 +22.1%
Inventory Days 399288291323 +11.0%
Days Payable 14198122110 -9.8%
Cash Conversion Cycle 367284255318 +24.7%
Working Capital Days 881127454 -27.0%
ROCE % 9%9%10%15% +50.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 53.73%53.73%53.73%53.73%44.28% -17.6%
FIIs 0.51%0.53%0.52%0.38%0.31% -18.4%
DIIs 0.02%0.00%0.01%0.00%0.08% —
Public 45.73%45.73%45.75%45.88%55.33% +20.6%
No. of Shareholders 11,81012,26012,60312,37311,685 -5.6%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Hester Biosciences Limited's revenue in Q1 FY27?
Hester Biosciences Limited reported revenue of ₹77 crore for the quarter ended June 2026 (Q1 FY27), down 8.4% from ₹84 crore in the same quarter last year, and down 23.1% sequentially over the March 2026 quarter.
What was Hester Biosciences Limited's net profit in Q1 FY27?
Net profit rose 460.8% year-on-year to ₹97 crore, from ₹17 crore. Earnings per share (EPS) came in at ₹114.00.
What is HESTERBIO's market capitalisation and P/E ratio?
At the current price of ₹2,236.50, HESTERBIO has a market capitalisation of ₹1,903 crore and a trailing P/E of about 13.9.
Who owns Hester Biosciences Limited? (shareholding pattern)
As of Sep 2026, promoters held 44.28%, foreign institutional investors (FIIs) 0.31%, domestic institutional investors (DIIs) 0.08%, public shareholders 55.33% of Hester Biosciences Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI